Joanne Weidhaas, M.D., Ph.D., M.S.M
Joanne is co-founder of MiraDx and Professor at the David Geffen School of Medicine at UCLA and head of translation research, in the Department of Therapeutic Radiology. Her pioneering research led to the co-discovery of the KRAS-variant, a strong predictor of cancer risk, tumor biology and treatment response. Her passion for empowering individuals to take charge of their health led her to found MiraDx, a genomics company dedicated to giving people and their doctors actionable information to prevent and better treat cancer. Joanne completed her oncology training at Memorial Sloan-Kettering Cancer Center in New York City and previously served as the Chief of the Breast Cancer Radiation Service at Yale Cancer Center and the Section Chief, Breast Cancer, Yale Cancer Center. She took a sabbatical while at Yale and completed a MBM at Stanford University. She has recently moved to UCLA as Division Head, Translational Research. Her dual role as a clinician and researcher enables her to apply genetic breakthroughs to the benefit of her patients. She currently lives in the LA area, with her husband and three children.
Frank Slack, Ph.D.
Frank is a co-founder of MiraDx and currently the Shields Warren Mallinckrodt Professor, Department of Pathology, and Director of the Institute for RNA Medicine, at BIDMC. His pioneering genetic research led to the discovery of “let-7,” one of the first microRNAs discovered, which he was able to show regulated cancer-causing genes. Dr. Slack is an internationally renown researcher and lecturer on microRNAs, one of the fastest-growing and exciting areas of genetic research.